Development of anti-cancer drug: past and future
Mano, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 73(Suppl 2): 11-15
2015
ISSN/ISBN: 0047-1852 PMID: 25831717 Document Number: 685729
Document emailed within 1 workday
Related Documents
Yamashita, T.; Iwata, K. 2009: New development in the treatment of breast cancer. II. Future anti-HER2 therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(13): 2551-2554Kumar, B.; Singh, S.; Skvortsova, I.; Kumar, V. 2017: Promising Targets in Anti-cancer Drug Development: Recent Updates Current Medicinal Chemistry 24(42): 4729-4752
Kiso, M.; Kawaoka, Y. 2012: Anti-influenza drug--current status and future prospects Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 8): 574-578
Beggs, W.H. 1993: Anti-Candida activity of the anti-cancer drug tamoxifen Research Communications in Chemical Pathology and Pharmacology 80(1): 125-128
Hegazy, S.K.; El-Azab, G.A.; Zakaria, F.; Mostafa, M.F.; El-Ghoneimy, R.A. 2022: Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer Life Sciences 299: 120536
Kelloff, G.J.; Crowell, J.A.; Boone, C.W.; Steele, V.E.; Lubet, R.A.; Greenwald, P.; Alberts, D.S.; Covey, J.M.; Doody, L.A.; Knapp, G.G. 1994: Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute Journal of Cellular Biochemistry. Supplement 20: 55-62
Zhang, J.; Li, H.-F.; Fan, W.; Liu, Z.; Man, S.-L.; Si, S.-Y.; Gao, W.-Y. 2014: Regularity of drugs compatibility of anti-hepatoma traditional Chinese medicine ancient prescriptions and risk evaluation of anti-hepatoma new drug research and development Zhongguo Zhong Yao Za Zhi 39(19): 3870-3875
Fushiki, H.; Hidaka, T.; Hori, S.; Fujimura, M.; Yamakawa, Y.; Izumi, R. 1998: Evaluation of a new anti-cancer drug regimen for endometrial cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(1): 75-78
Ottenheijm, H.C.; van den Broek, L.A. 1988: The development of sparsomycin as an anti-tumour drug Anti-Cancer Drug Design 2(4): 333-337
Tominaga, T. 1999: Recent development of oral anti-cancer drugs for breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(3): 301-307
Pantazis, P.; Han, Z.; Balan, K.; Wang, Y.; Wyche, J.H. 2003: Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models Anticancer Research 23(5a): 3623-3638
Wunder, A.; Thiele, A.; Koslowski, M.; Gantner, F.; Niessen, H. 2014: Nuclear imaging to support anti-inflammatory drug discovery and development Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 2014
Michaelis, M.; Doerr, H.W.; Cinatl, J. 2007: Valproic acid as anti-cancer drug Current Pharmaceutical Design 13(33): 3378-3393
Zwiebel, J. 2016: The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program Clinical Advances in Hematology and Oncology: H&o 14(3): 157-159
Hirai, F. 2015: III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 940-943
Funato, T. 1997: Reversal of drug resistance in human cancer cells by anti-oncogenes Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(4): 395-400
Inoue, A. 2015: Report of serious adverse drug reaction induced by anti-cancer agents Nihon Rinsho. Japanese Journal of Clinical Medicine 73 Suppl. 2: 67-72
Thakur, S.S. 2018: Anti-Cancer Drug Discovery: Structure, Function and Novel Strategy - (Part-I) Current Topics in Medicinal Chemistry 18(30): 2543
Thakur, S.S. 2019: Anti-Cancer Drug Discovery: Structure, Function and Novel Strategy - Part-II Current Topics in Medicinal Chemistry 19(17): 1490
Gräfe, K.A.; Hoffmann, H. 2000: Development and validation of an indirect enzyme-linked immunosorbent assay (ELISA) for the nonsteroidal anti-inflammatory drug S-ibuprofen Die Pharmazie 55(4): 286-292